The role of technology in obeying different types of treatment of insulin-dependent diabetes mellitus

Not Applicable

• Conditions: Diabetes mellitus; C18.452.394.750.714; C18.452.394.750.124

• Registration Number: RBR-6qx7m5
• Lead Sponsor: Faculdade de Ciências Médicas da Santa Casa de São Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-04-22
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients under following at ADO with type 1 DM or LADA. Any age. Any A1C. Use of insulin analogues (ultra-slow - Detemir, Glargina 100, Glargina 300, Degludeca - and ultrafast - Glulisine, Aspart or Lispro). In the subgroup of patients under carbohydrate counts, those who have had this modality of treatment for at least 3 (three) months. In the subgroup of patients undergoing treatment with CSII, those who have had this treatment modality for at least 3 (three) months.

Exclusion Criteria

Patients with other types of DM than those previously mentioned. Patients who use insulin, but not in MDI scheme. Patients treated with conventional insulin (NPH - Neutral Protamine Hagedorn - and regular), although in an MDI scheme.

Study & Design

• Study Type: Intervention
• Study Design: Not specified